ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Phase I Trial of Intratumoral Injection of
Open access · greenAbstract readClinical Trial, Phase I
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 156 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
156citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
156 citing papers in PubMed, 1 synthesis or guideline pooled it, 222 citations in OpenAlex.
- Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.The Cochrane database of systematic reviews · 2021Pooled it
- Efficacy of Enhanced Cytokine-Induced Killer Cells as an Adjuvant Immunotherapy for Renal Cell Carcinoma: Preclinical and Clinical Studies.Journal of healthcare engineering · 2021Trial
- CD8⁺ T Cell infiltration and spatial organization in cancer: mechanisms, barriers, and therapeutic strategies.Molecular biomedicine · 2026Review
- Bronchoscopic Ablation and Intratumoral Therapies for Lung Cancer: Expanding Local Treatment Beyond Surgical Resection.Cancers · 2026Review
- Endobronchial Intratumoral Immuno- and Gene Therapies in Lung Cancer: Mechanisms of Local Delivery, Systemic Immune Effects, and Global Feasibility.International journal of molecular sciences · 2026Review
- Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal transduction and targeted therapy · 2026Review
- Tertiary lymphoid structures in breast cancer: Mechanistic insights, subtype-specific patterns, and therapeutic implications.World journal of surgical oncology · 2026Review
- FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer.Journal for immunotherapy of cancer · 2026Article
- Neoadjuvant intratumoral immune stimulation using gene-mediated cytotoxic immunotherapy for resectable non-small cell lung cancer: 5-Year outcomes.JTCVS open · 2026Article
- Immunocyte reprogramming empowers live-cell drug delivery: Mechanistic insights, delivery strategies, and clinical perspectives.Acta pharmaceutica Sinica. B · 2026Review
- Dendritic cells: the central partner for cancer immunity.Oncoimmunology · 2025Review
- Dendritic Cell Therapy in Immuno-Oncology: A Potentially Key Component of Anti-Cancer Immunotherapies.Cancers · 2025Review
- Spatiotemporally controlled delivery of biomacromolecules via injectable hydrogels for precision modulation of the tumor immune microenvironment.Journal of nanobiotechnology · 2025Review
- Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors.Nature communications · 2025Article
- Extracellular Vesicle-Based mRNA Therapeutics and Vaccines.Exploration (Beijing, China) · 2025Review
- Exploring the Pivotal Functions of Tertiary Lymphoid Structures in Cancer Prognosis and Immunotherapy Outcomes.Cancers · 2025Review
- Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future.International journal of molecular sciences · 2025Review
- Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential.MedComm · 2025Review
- Turning cold tumors into hot tumors to ignite immunotherapy.Molecular cancer · 2025Review
- Tertiary Lymphoid Structures Across Organs: Context, Composition, and Clinical Levers.Immunological reviews · 2025Review
96 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 3 institutions in 1 country.
Jay M LeeLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California. jaymoonlee@mednet.ucla.edu sdubinett@mednet.ucla.edu.
Mi-Heon LeeLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
Edward GaronDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Jonathan W GoldmanDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Ramin Salehi-RadDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Felicita E BaratelliDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Dörthe SchaueDepartment of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Gerald WangLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
Fran RosenLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
Jane YanagawaLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
Tonya C WalserLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
Ying LinLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
Stacy J ParkLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
Sharon AdamsDepartment of Transfusion Medicine, NIH, Bethesda, Maryland.
Francesco M MarincolaDepartment of Transfusion Medicine, NIH, Bethesda, Maryland.
Paul C TumehLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
Fereidoun AbtinDepartment of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Robert SuhDepartment of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Karen L ReckampDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California.
Gina LeeLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
William D WallaceDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Sarah LeeDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Gang ZengDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.
David A ElashoffLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
Sherven SharmaLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California.
Steven M DubinettLung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California. jaymoonlee@mednet.ucla.edu sdubinett@mednet.ucla.edu.
University of California, Los Angeles · USCity Of Hope National Medical Center · USInstitute for Transfusion Medicine · US
Funding
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MUCLA SPORE IN LUNG CANCERP50CA090388 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2001 to 2008
$13.0MUCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3MUCLA Pulmonary and Critical Care Medicine Training ProgramT32HL072752 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JOHN A BELPERIO, TOMAS GANZ · 2003 to 2026
$8.3MIntegrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung CancerU01CA196408 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ABERLE, DENISE R., DUBINETT, STEVEN M. · 2015 to 2021
$7.1MA model for predicting response to PD-1 inhibitors in NSCLCR01CA208403 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GARON, EDWARD B · 2017 to 2021
$3.2MThe Boston University-UCLA Lung Cancer Biomarker Development LabU01CA214182 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ABERLE, DENISE R., DUBINETT, STEVEN M. · 2016 to 2021
$3.1MGENETIC IMMUNOTHERAPY FOR LUNG CANCERR01CA085686 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2001 to 2004
$1.1MA Phase I Trial of CCL-21 Gene Modified DC in NSCLCR21CA105705 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2003 to 2007
$671kInflammation in the pathogenesis of lung cancerI01BX000359 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI DUBINETT, STEVEN M. · 2009 to 2018
–Intratumoral genetic therapy for lung cancerI01CX000345 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI DUBINETT, STEVEN M. · 2012 to 2021
–BLRD VA I01 BX000359CSRD VA I01 CX000345NCATS NIH HHS UL1 TR001881NCI NIH HHS P50 CA090388NCI NIH HHS R01 CA085686NCI NIH HHS R01 CA208403NCI NIH HHS R21 CA105705NCI NIH HHS T32 CA009120NCI NIH HHS U01 CA196408NCI NIH HHS U01 CA214182NHLBI NIH HHS T32 HL072752
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedB7-H1 AntigenCancer VaccinesCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesChemokine CCL21Cohort StudiesDendritic CellsDyspneaFemaleHumansImmunotherapy, AdoptiveInjections, IntralesionalInterferon-gammaLung NeoplasmsB7-H1 AntigenCancer VaccinesCCL21 protein, humanCD274 protein, humanChemokine CCL21Interferon-gamma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.